Mar 22, 2023 7:20am EDT

Medexus Announces New License Deal for Topical Terbinafine

Mar 08, 2023 5:00pm EST

Medexus Announces US$58.5 million in New Credit Facilities

Mar 06, 2023 8:00am EST

Medexus to Participate in 35th Annual Roth Conference

Feb 08, 2023 5:00pm EST

Medexus Announces Another Record Quarter with Fiscal Q3 2023 Revenue of US$28.7 Million, a 35% Increase Over Fiscal Q3 2022

Feb 06, 2023 5:00pm EST

Medexus Welcomes Two New Board Members

Feb 01, 2023 5:00pm EST

Medexus Secures Public Reimbursement for Cuvposa® in Quebec

Jan 31, 2023 5:00pm EST

Medexus Schedules Third Fiscal Quarter 2023 Conference Call

Jan 12, 2023 7:30am EST

Medexus Expects Record Revenue for Fiscal Q3 2023 and Provides Business Update

Nov 08, 2022 5:30pm EST

Medexus Announces Strongest Quarter in Company History with Fiscal Q2 2023 Revenue of US$27.7 Million, a 55% Increase Over Fiscal Q2 2022

Nov 02, 2022 8:00am EDT

Medexus Schedules Second Quarter 2023 Conference Call